HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestle's Prospects To Lead OTC Acne Market Gel With Differin Approval

This article was originally published in The Pink Sheet

Executive Summary

Differin Gel, the first NDA approved OTC acne treatment, could make Nestle the runaway leader in the market. The Swiss firm's Nestle Skin Health business owns Differin maker Galderma and has a majority stake in a JV marketing Proactiv.

You may also be interested in...



OTC Oral Contraceptive In US Would Bring Market Uncertainties Along With Public Health Benefits

Perrigo is the top potential marketer of the first OTC oral contraceptive in the US by acquiring HRA Pharma, which is preparing a switch NDA and earlier in 2021 gained UK regulatory approval for pharmacy sales of a progestin-only contraceptive, desogestrel.

US FDA Beats Clock On NDAC Charter Renewal

Give agency credit for beating the expiration date after missing it in previous renewals.

Galderma Pioneers NDA Path Into OTC Acne Treatment Market

FDA on July 8 announces approval for Galderma Laboratories to market Differin Gel 0.1% (adapalene) as an OTC, once-daily topical for treatment of acne by consumers 12 years old and up.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS123169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel